Clinical Trial Update: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating cemiplimab in combination with palbociclib for advanced or unresectable dedifferentiated liposarcoma; the trial is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Soft Tissue Sarcoma of the Trunk and Extremities
• Unresectable Dedifferentiated Liposarcoma

Drugs mentioned

• Ibrance (palbociclib) (palbociclib)
• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING